Tested Applications
| Positive WB detected in | MKN-45 cells, human liver tissue, human brain tissue, SW 1990 cells, A549 cells, U2OS cells |
| Positive IP detected in | U2OS cells |
| Positive IHC detected in | human intrahepatic cholangiocarcinoma tissue Note: suggested antigen retrieval with TE buffer pH 9.0; (*) Alternatively, antigen retrieval may be performed with citrate buffer pH 6.0 |
Recommended dilution
| Application | Dilution |
|---|---|
| Western Blot (WB) | WB : 1:500-1:3000 |
| Immunoprecipitation (IP) | IP : 0.5-4.0 ug for 1.0-3.0 mg of total protein lysate |
| Immunohistochemistry (IHC) | IHC : 1:50-1:500 |
| It is recommended that this reagent should be titrated in each testing system to obtain optimal results. | |
| Sample-dependent, Check data in validation data gallery. | |
Published Applications
| KD/KO | See 1 publications below |
| WB | See 3 publications below |
| IHC | See 1 publications below |
Product Information
13168-1-AP targets DCBLD2 in WB, IHC, IP, ELISA applications and shows reactivity with human samples.
| Tested Reactivity | human |
| Cited Reactivity | human, mouse |
| Host / Isotype | Rabbit / IgG |
| Class | Polyclonal |
| Type | Antibody |
| Immunogen |
CatNo: Ag3821 Product name: Recombinant human DCBLD2 protein Source: e coli.-derived, PGEX-4T Tag: GST Domain: 519-743 aa of BC029658 Sequence: YDLPYWDRAGFYLMVSLACRHNEGWWKGMKQFLPAKAVDHEETPVRYSSSEVNHLSPREVTTVLQADSAEYAQPLVGGIVGTLHQRSTFKPEEGKEAGYADLDPYNSPGQEVYHAYAEPLPITGPEYATPIIMDMSGHPTTSVGQPSTSTFKATGNQPPPLVGTYNTLLSRTDSCSSAQAQYDTPKAGKPGLPAPDELVYQVPQSTQEVSGAGRDGECDVFKEIL Predict reactive species |
| Full Name | discoidin, CUB and LCCL domain containing 2 |
| Calculated Molecular Weight | 775 aa, 89 kDa |
| Observed Molecular Weight | 93 kDa, 127 kDa |
| GenBank Accession Number | BC029658 |
| Gene Symbol | DCBLD2 |
| Gene ID (NCBI) | 131566 |
| RRID | AB_2292662 |
| Conjugate | Unconjugated |
| Form | Liquid |
| Purification Method | Antigen affinity purification |
| UNIPROT ID | Q96PD2 |
| Storage Buffer | PBS with 0.02% sodium azide and 50% glycerol, pH 7.3. |
| Storage Conditions | Store at -20°C. Stable for one year after shipment. Aliquoting is unnecessary for -20oC storage. 20ul sizes contain 0.1% BSA. |
Background Information
DCBLD2 (also known as CLCP1 or ESDN) is a transmembrane protein belonging to the DCBLD family, characterized by extracellular discoidin, CUB, and LCCL domains. It plays roles in cell adhesion, signaling, and vascular biology, with emerging implications in cancer progression, angiogenesis, and cardiovascular diseases. DCBLD2 is upregulated in certain tumors (e.g., glioblastoma, lung cancer) and may regulate receptor tyrosine kinase (RTK) pathways, including EGFR and PDGFR. Its exact mechanisms remain under investigation, but it is suggested to influence cell migration, proliferation, and tumor microenvironment interactions. The human DCBLD2 protein has a predicted molecular mass of ∼80 kDa based on its amino acid sequence, although it regularly displays an effective molecular mass of ∼130 kDa via SDS-PAGE (PMID: 30902898).
Protocols
| Product Specific Protocols | |
|---|---|
| IHC protocol for DCBLD2 antibody 13168-1-AP | Download protocol |
| IP protocol for DCBLD2 antibody 13168-1-AP | Download protocol |
| WB protocol for DCBLD2 antibody 13168-1-AP | Download protocol |
| Standard Protocols | |
|---|---|
| Click here to view our Standard Protocols |
Publications
| Species | Application | Title |
|---|---|---|
Environ Toxicol Comprehensive analyses and experimental verification of NETs and an EMT gene signature for prognostic prediction, immunotherapy, and chemotherapy in pancreatic adenocarcinoma
| ||
Aging (Albany NY) Plumbagin has an inhibitory effect on the growth of TSCC PDX model and it enhances the anticancer efficacy of cisplatin | ||
Am J Cancer Res In silico development and in vitro validation of a novel five-gene signature for prognostic prediction in colon cancer |
